Group 1 - The immunotherapy sector is experiencing a strong rebound, with companies like Zhongyuan Qihuo and Kaineng Health hitting the daily limit up [1] - Other companies in the sector, such as Jimin Health, Guanhao Bio, Chengda Pharmaceutical, Zexing Pharmaceutical, and Heyuan Bio, are also showing significant gains [1]

Group 1 - The cell immunotherapy sector experienced a significant rally in the afternoon, with Kaineng Health hitting a 20% limit up, and Jimin Health, Zhongyuan Qihe, and Nanjing Xinbai also previously reaching their limit up [1] - Sanyuan Gene saw an increase of over 10%, while Chengda Pharmaceutical and Sunshine Nuohe also followed the upward trend [1] - A recent research paper published in the journal Nature Biotechnology indicates that low-intensity ultrasound treatment can eliminate neurotoxic debris in the brains of mice induced with hemorrhagic stroke [1]

Core Viewpoint - The company, Jimin Health (603222), has stated that the number of shareholders at the end of each quarter will be disclosed in regular reports, and shareholders can request information for specific dates by providing proof of shareholding [1] Summary by Categories - **Shareholder Information Disclosure** - The company will disclose the number of shareholders at the end of each quarter in its periodic reports [1] - Shareholders wishing to obtain the number of shareholders for other specific dates must provide written documentation proving the type and quantity of shares held [1] - The company will verify the identity of shareholders before providing the requested information [1]

Core Points - Jimin Health's stock price increased by 2.08% on November 11, reaching 10.33 CNY per share, with a market capitalization of 5.424 billion CNY [1] - The company has seen a year-to-date stock price increase of 52.14%, with a recent 5-day increase of 3.20% and a 60-day increase of 45.90% [1] - Jimin Health has appeared on the trading leaderboard 13 times this year, with the latest occurrence on September 11, where it recorded a net purchase of 66.0795 million CNY [1][2] Financial Performance - For the period from January to September 2025, Jimin Health reported a revenue of 545 million CNY, a year-on-year decrease of 20.21%, and a net profit of -77.1504 million CNY, a decrease of 371.51% [2] - The company has distributed a total of 127 million CNY in dividends since its A-share listing, with 10.7447 million CNY distributed in the last three years [3] Shareholder Information - As of September 30, Jimin Health had 58,100 shareholders, an increase of 107% from the previous period, with an average of 9,035 circulating shares per shareholder, a decrease of 51.69% [2] Business Overview - Jimin Health, established on December 24, 1996, and listed on February 17, 2015, is primarily engaged in the research, production, and sales of medical devices, medical services, and large-volume intravenous products [1] - The company's revenue composition includes 52.07% from pharmaceutical manufacturing, 46.01% from medical services, 1.54% from pharmaceutical trading, and 0.38% from other sources [1] Industry Classification - Jimin Health is classified under the pharmaceutical and biological industry, specifically in medical devices and consumables, with involvement in innovative drugs, cell therapy, in vitro diagnostics, antigen testing, and medical devices [2]

Core Viewpoint - Jimin Health announced on November 5 that the company will consider share buybacks based on market conditions [2] Group 1 - The company is actively engaging with investors through an interactive platform [2] - The decision to repurchase shares will be contingent on market circumstances [2]

Group 1 - The company plans to leverage the innovative policies of the Boao Lecheng Pilot Zone in Hainan to enhance external cooperation [2] - The company aims to increase investment in the research and development of innovative drugs [2] - The company intends to develop the Boao International Hospital into a high-level clinical research center and translational medicine platform [2]

Core Viewpoint - The company has announced its third-quarter financial report, emphasizing the accuracy and completeness of the information provided by its board and management, while also detailing its share repurchase plan and ongoing legal issues related to a fraud case [2][6][7]. Financial Data - The financial report for the third quarter is unaudited, and the company has provided key financial data and indicators in RMB [3][8]. - As of September 30, 2025, the company has repurchased a total of 2,005,500 shares, with a total expenditure of 12.089 million RMB (excluding transaction fees) [7]. Share Repurchase Plan - The company plans to repurchase shares using its own funds through centralized bidding, with a maximum price of 10.00 RMB per share and a total repurchase amount between 100 million RMB and 200 million RMB, to be completed within 12 months from the board's approval [6][7]. Legal Issues - The company is currently facing 14 lawsuits from primary distributors involving a total of 69.5026 million RMB, and 10 lawsuits from secondary distributors involving 17.0766 million RMB, related to a case of forgery involving a former employee [7].

（编辑 姚尧） 证券日报网讯 10月31日晚间，济民健康发布公告称，公司于近日收到双鸽集团有限公司（以下简称"双 鸽集团"）通知，双鸽集团在浙商银行股份有限公司台州分行质押的17，640，000股股份办理了解除质 押手续。 ...

Core Points - Jimin Health announced that it will not implement a share buyback in October 2025 [2] Group 1 - The company released an announcement on October 31 regarding its decision on share repurchase [2]

Group 1 - The core point of the news is that Jimin Health (SH 603222) announced the release of 17.64 million shares from pledge by its major shareholder, Shuangge Group, which holds approximately 123 million shares, accounting for 23.38% of the total share capital [1] - After the release of the pledge, Shuangge Group has a total of 76.5 million shares pledged, which is 62.32% of its holdings and 14.57% of the total share capital [1] - The combined shareholding of Shuangge Group and its concerted parties is about 229 million shares, representing 43.52% of the total share capital [1] Group 2 - As of the announcement, Jimin Health's market capitalization is 5.4 billion yuan [2] - For the first half of 2025, Jimin Health's revenue composition is as follows: 52.07% from the pharmaceutical manufacturing sector, 46.01% from the medical services sector, 1.54% from pharmaceutical trading, and 0.38% from other businesses [1]